PMV PHARMACEUTICALS INC

PMVPNASDAQ

🏆 #4230 by market capEarnings Nov 10US Equity

$742.68▼ $21.09 (−2.84%)

Simulated price

🔔

Track PMVP

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 2.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$76M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

No chart data available for PMVP.

Trading Snapshot

Day Range: $732.64 – $747.36
52-Week Range: $1.02 – $1.88
Volume: $2.73B
Avg Volume: $2.21B
Shares Outstanding: 53.3M
Next Earnings: Nov 20, 2026

Fundamentals Snapshot

Annual Revenue: $11M
Last Q Revenue: $3M
P/E Ratio: -1.0
P/S Ratio: 0.0x
EPS (TTM): $-1.41
Dividend Yield: 0.00%
Dilution (1yr): +3.3%

Why Investors Own PMVP

✓High-growth profile — revenue up +28.7% YoY with expanding US Equity exposure.
✓Healthy economics — 43% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PMV PHARMACEUTICALS INC

PMVP

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$86M▲ +0.9% YoY

Free Cash Flow

−$74M▲ +41.7% YoY

Shares Outstanding

53.3M▲ +3.3% YoY

Net Cash

$37M▼ −$3M YoY

StockOtter · stockotter.space

About PMV PHARMACEUTICALS INC

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

🦦